Ceprotin (protein c) Disease Interactions
There are 2 disease interactions with Ceprotin (protein c):
Protein C concentrate human (applies to Ceprotin) bleeding
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect
In clinical studies, several bleeding episodes have been observed with the use of protein C concentrate human. Simultaneous administration of protein C concentrate human and tissue plasminogen activator (tPA) may further increase the risk of bleeding from tPA, specially in those at risk. Care should be taken when using this agent in patients at risk of bleeding.
Protein C concentrate human (applies to Ceprotin) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Protein C concentrate human contains sodium >200 mg. Inform patients on a low sodium diet that the quantity of sodium in the maximum daily dose of protein C concentrate human exceeds 200 mg. Care should be exercised when using this agent in patients with renal impairment due to the risk of sodium overload or those on a low sodium diet.
Ceprotin (protein c) drug interactions
There are 34 drug interactions with Ceprotin (protein c)
More about Ceprotin (protein c)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: miscellaneous coagulation modifiers
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|